118 related articles for article (PubMed ID: 38184241)
1. Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study.
Morand GB; Tessler I; Noik M; Krasner J; Yamin T; Pusztaszeri MP; Avior G; Payne RJ
Endocr Pract; 2024 Apr; 30(4):319-326. PubMed ID: 38184241
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer.
Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review.
Hier J; Avior G; Pusztaszeri M; Krasner JR; Alyouha N; Forest VI; Hier MP; Mlynarek A; Richardson K; Sadeghi N; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Apr; 50(1):29. PubMed ID: 33910629
[TBL] [Abstract][Full Text] [Related]
4. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
Chiosea S; Hodak SP; Yip L; Abraham D; Baldwin C; Baloch Z; Gulec SA; Hannoush ZC; Haugen BR; Joseph L; Kargi AY; Khanafshar E; Livhits MJ; McIver B; Patel K; Patel SG; Randolph GW; Shaha AR; Sharma J; Stathatos N; van Zante A; Carty SE; Nikiforov YE; Nikiforova MN
J Clin Endocrinol Metab; 2023 Oct; 108(11):2999-3008. PubMed ID: 37071871
[TBL] [Abstract][Full Text] [Related]
5. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
[TBL] [Abstract][Full Text] [Related]
6. Unique Molecular Signatures Are Associated with Aggressive Histology in Pediatric Differentiated Thyroid Cancer.
Mollen KP; Shaffer AD; Yip L; Monaco SE; Huyett P; Viswanathan P; Witchel SF; Duvvuri U; Simons JP
Thyroid; 2022 Mar; 32(3):236-244. PubMed ID: 34915753
[No Abstract] [Full Text] [Related]
7. Diagnostic Value and Challenges of BRAF V600E Molecular Testing and Thyroid Fine-Needle Aspiration Cytology: A Retrospective Study from a Tertiary Institution in Southern Hunan Province, China.
Lan Z; Yang F; Zhang J; Lan Y; Li H; He R
Acta Cytol; 2023; 67(6):629-638. PubMed ID: 37708867
[TBL] [Abstract][Full Text] [Related]
8. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology.
Skaugen JM; Taneja C; Liu JB; Wald AI; Nikitski AV; Chiosea SI; Seethala RR; Ohori NP; Karslioglu-French E; Carty SE; Nikiforova MN; Yip L; Nikiforov YE
Thyroid; 2022 Dec; 32(12):1500-1508. PubMed ID: 35864811
[No Abstract] [Full Text] [Related]
9. Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules.
Spaulding SL; Maayah M; Dinauer CA; Prasad M; Darbinyan A; Morotti R; Christison-Lagay ER
J Pediatr Surg; 2024 May; 59(5):975-980. PubMed ID: 38246817
[TBL] [Abstract][Full Text] [Related]
10. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma.
Kakarmath S; Heller HT; Alexander CA; Cibas ES; Krane JF; Barletta JA; Lindeman NI; Frates MC; Benson CB; Gawande AA; Cho NL; Nehs M; Moore FD; Marqusee E; Kim MI; Larsen PR; Kwong N; Angell TE; Alexander EK
J Clin Endocrinol Metab; 2016 Dec; 101(12):4938-4944. PubMed ID: 27689252
[TBL] [Abstract][Full Text] [Related]
12. Significance of FNAC, BRAF mutation, and intraoperative frozen section in surgical decision-making of thyroid nodules.
Zhu Z; Su C; Chen G; Wan F; Jin M; Duan X; Wang Y; Wang G
Diagn Cytopathol; 2023 Jul; 51(7):441-448. PubMed ID: 37042168
[TBL] [Abstract][Full Text] [Related]
13. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
14. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
[TBL] [Abstract][Full Text] [Related]
15. Association of Bethesda category and molecular mutation in patients undergoing thyroidectomy.
Mascarella MA; Peeva M; Forest VI; Pusztaszeri MP; Avior G; Tamilia M; Mlynarek AM; Hier MP; Payne RJ
Clin Otolaryngol; 2022 Jan; 47(1):75-80. PubMed ID: 34510770
[TBL] [Abstract][Full Text] [Related]
16. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
[TBL] [Abstract][Full Text] [Related]
17. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.
Hu MI; Waguespack SG; Dosiou C; Ladenson PW; Livhits MJ; Wirth LJ; Sadow PM; Krane JF; Stack BC; Zafereo ME; Ali SZ; Weitzman SP; Hao Y; Babiarz JE; Kennedy GC; Kloos RT
J Clin Endocrinol Metab; 2021 Jul; 106(8):2198-2207. PubMed ID: 34009369
[TBL] [Abstract][Full Text] [Related]
18. Does bethesda category predict aggressive features in malignant thyroid nodules?
Kleiman DA; Beninato T; Soni A; Shou Y; Zarnegar R; Fahey TJ
Ann Surg Oncol; 2013 Oct; 20(11):3484-90. PubMed ID: 23812773
[TBL] [Abstract][Full Text] [Related]
19. Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules.
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
World J Surg; 2020 Jul; 44(7):2264-2271. PubMed ID: 32227276
[TBL] [Abstract][Full Text] [Related]
20. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
